Procyon Advisors LLC Sells 20,904 Shares of Becton, Dickinson and Company $BDX

Key Points

• Procyon Advisors LLC significantly reduced its stake in Becton, Dickinson and Company by 88.6% in Q2, selling 20,904 shares and retaining only 2,679 shares valued at approximately $461,000.
• Insider selling has also occurred, with Director Claire Fraser selling 917 shares and EVP Michael David Garrison selling 1,185 shares, indicating a decrease in ownership for both.
• Becton, Dickinson and Company reported earnings of $3.68 per share for the last quarter, surpassing estimates and demonstrating a 10.4% year-over-year revenue increase.

Procyon Advisors LLC lessened its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 88.6% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,679 shares of the medical instruments supplier's stock after selling 20,904 shares during the quarter. Procyon Advisors LLC's holdings in Becton, Dickinson and Company were worth $461,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in BDX. Pallas Capital Advisors LLC raised its stake in shares of Becton, Dickinson and Company by 197.2% during the 2nd quarter. Pallas Capital Advisors LLC now owns 6,607 shares of the medical instruments supplier's stock valued at $1,138,000 after purchasing an additional 4,384 shares during the period. Financiere des Professionnels Fonds d investissement inc. lifted its holdings in shares of Becton, Dickinson and Company by 11.4% during the 2nd quarter. Financiere des Professionnels Fonds d investissement inc. now owns 101,333 shares of the medical instruments supplier's stock valued at $17,455,000 after buying an additional 10,355 shares during the period. Czech National Bank boosted its stake in shares of Becton, Dickinson and Company by 6.2% in the second quarter. Czech National Bank now owns 70,056 shares of the medical instruments supplier's stock worth $12,067,000 after acquiring an additional 4,106 shares during the period. Apella Capital LLC grew its position in Becton, Dickinson and Company by 4.9% in the second quarter. Apella Capital LLC now owns 1,616 shares of the medical instruments supplier's stock worth $279,000 after acquiring an additional 76 shares in the last quarter. Finally, Bard Financial Services Inc. purchased a new stake in shares of Becton, Dickinson and Company in the second quarter valued at approximately $790,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Argus increased their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Morgan Stanley raised their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Wells Fargo & Company boosted their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a report on Friday, August 8th. Finally, Barclays lowered their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Four equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, Becton, Dickinson and Company has an average rating of "Hold" and an average price target of $213.30.

Becton, Dickinson and Company Price Performance

BDX traded down $1.49 on Monday, reaching $185.55. 233,293 shares of the company's stock were exchanged, compared to its average volume of 2,533,917. The stock's fifty day moving average price is $187.65 and its 200-day moving average price is $189.91. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The stock has a market cap of $53.18 billion, a PE ratio of 33.39, a P/E/G ratio of 1.51 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's payout ratio is presently 74.82%.

Insider Activity

In other news, Director Claire Fraser sold 917 shares of the company's stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares of the company's stock, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,965 shares of company stock valued at $551,536 in the last ninety days. Corporate insiders own 0.36% of the company's stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.